Trump signs order on psychedelics

The new White House directive aims to fast-track clinical trials and 'Right to Try' access for psychedelic drugs to treat conditions like PTSD and depression.

Companies like Compass Pathways and AtaiBeckley saw their stock prices spike by over 30% as the administration moves to deregulate the sector.

FDA Commissioner Dr. Marty Makary stated that promising research into these substances could transform mental health care for veterans and other vulnerable populations.

This move follows the administration's previous efforts to reclassify marijuana and could signal a broader shift in federal drug policy.